EyePointEYPT -0.36%34 Days Payable is 2,532.10 as of Mar. 2026, which is 423% above its 10-year median of 484.40. GuruFocus rates EYPT with a GF Score™ of 34/100 and a GF Value™ of $0.83 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 706 Biotechnology companies, EyePoint ranks better than 91.64% on this metric.
EyePoint's average Accounts Payable for the
three
months ended in Mar. 2026 was $14.65 Mil. EyePoint's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.53 Mil.
Hence, EyePoint's Days Payable for the
three
months ended in Mar. 2026 was 2,532.10.
The historical rank and industry rank for EyePoint's Days Payable or its related term are showing as below:
EYPT'
s Days Payable Range Over the Past 10 Years
Min: 272.2 Med: 484.4 Max: 3080.08
Current: 3080.08
During the past 13 years, EyePoint's highest Days Payable was 3080.08. The lowest was 272.20. And the median was 484.40.
EYPT's Days Payable is ranked better than 91.64% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs EYPT: 3080.08
EyePoint's Days Payable
increased
from Mar. 2025 (1,594.89) to Mar. 2026 (2,532.10).
It may suggest that EyePointdelayed paying its suppliers.
EyePoint Days Payable Related Terms
EyePoint Days Payable Historical Data
* Premium members only.
The historical data trend for EyePoint's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, EyePoint's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EyePoint Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EyePoint's Days Payable distribution charts can be found below:
* The bar in red indicates where EyePoint's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
EyePoint's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint (EYPT) has a Days Payable of 2,532.10 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on EyePoint and its competitors. This is 423% above median its historical median of 484.40. Over the past decade, EyePoint's Days Payable has ranged from 272.20 to 3,080.08. According to the industry distribution chart, EyePoint ranks #59 out of 706 companies in the Biotechnology industry, placing it in the top 8.4%.
Is EyePoint's Days Payable too high?
EyePoint's current Days Payable of 2,532.10 is 423% above median its 10-year median of 484.40. Over the past 10 years, this metric has ranged from a low of 272.20 to a high of 3,080.08. The Biotechnology industry median Days Payable is 113.56. EyePoint's value of 2,532.10 is 2129.7% above this industry median. Based on the distribution chart, EyePoint ranks #59 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, EyePoint has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Days Payable compare to AKTS and OLMA?
According to the Biotechnology industry distribution chart, EyePoint ranks #59 out of 706 companies for Days Payable. This places EyePoint in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. EyePoint's value of 2,532.10 is 2129.7% above this benchmark. Historically, EyePoint's own Days Payable has ranged from 272.20 to 3,080.08 over the past decade. While the company's 10-year median is 484.40 vs. the industry median of 113.56, EyePoint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EyePoint's current Days Payable of 2,532.10 is 2129.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on EyePoint and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EyePoint's current Days Payable is 2,532.10, which is 423% above median its own 10-year median of 484.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $13.66 — trading 1545.8% above its estimated fair value. The current Days Payable is 2,532.10, which is 423% above median its 10-year median of 484.40 and 2129.7% above the Biotechnology industry median of 113.56. EyePoint's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For EyePoint (EYPT), the current Days Payable is 2,532.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EyePoint (EYPT) Overvalued in 2026?
Based on GuruFocus' analysis, EyePoint stock appears to be overvalued.
The current stock price of $13.66 is trading 1545.8% above its estimated GF Value™ of $0.83.
GuruFocus considers EyePoint to be Significantly Overvalued.
Key valuation signals for EYPT:
Days Payable: 2,532.10 (423% above median its 10-year median of 484.40)
GF Value™: $0.83 vs. price of $13.66 (1545.8% above fair value)
Industry Position: 2129.7% above the Biotechnology median (#59 of 706)
No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score
Get the complete analysis for EYPT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EYPT has been successfully added to your 
